SynthesisBMJ open2020

What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.

Guanghui Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.